Dosage CO-NORTIVAN

Medications "a" Medication "b" Medications "c" Medications "d" Drugs "e" Grindeks" Medications "g" Medications "h" Medications "i" Medications "j" urinary tract infection symptoms Medications "k" Medications "l" Medications " m 'Drugs' n 'Drugs' o 'Drugs' p 'Medications' r 'Medicine' s "Medicine" z "Drugs" t "Medications" u "Medications" v "Medications" w "Drugs" q "Medications" x " Medications "y"
CO-NORTIVAN 80 / 12.5 mg film-coated tablets NORTIVAN CO-160 / 12.5 mg film-coated tablets CO-NORTIVAN urinary tract infection symptoms 160/25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION urinary tract infection symptoms
Each tablet contains 80 mg of valsartan urinary tract infection symptoms and 12.5 mg of hydrochlorothiazide. Each tablet contains 160 mg of valsartan and hydrochlorothiazide 12.5 mg Each tablet contains 160 mg of valsartan and hydrochlorothiazide 25 mg. INN. Valsartanum, hydrochlorothiazide tablet contains 29.72 mg tablet contains 71.94 mg 0.5 mg lecithin urinary tract infection symptoms (contains soybean oil), and 0.56 mg of sunset yellow FCF ingredients: Each NORTIVAN CO-80 / 12.5 mg film-coated lactose and 0.25 mg lecithin (contains soybean oil). Each NORTIVAN CO-160 / 12.5 mg film-coated lactose monohydrate (E110). Each CO-NORTIVAN 160/25 mg film-coated lactose monohydrate and 0.5 mg of lecithin (contains soybean oil). 59.44 mg tablet contains a full list of excipients, urinary tract infection symptoms see section 6.1. 3. PHARMACEUTICAL FORM
Film-coated tablet. CO-NORTIVAN 80 / 12.5 mg: pink, oval, biconvex, film-coated tablets (11 x 5.8 mm), which is written on one side of the "V" urinary tract infection symptoms on one side and "H". NORTIVAN CO-160 / 12.5 mg: the color red, oval, biconvex, film-coated urinary tract infection symptoms tablets (15 x 6 mm), which is written on one side of the "V" on one side and "H". CO-NORTIVAN 160/25 mg: orange-colored, oval, biconvex, film-coated tablets (15 x 6 mm), which is written on one side of the "V" on one side and "H". 4. CLINICAL PARTICULARS 4.1 Therapeutic indications
Treatment of essential hypertension in adults. CO-NORTIVAN fixed-dose combination is indicated in patients whose blood pressure urinary tract infection symptoms is not adequately controlled on valsartan or hydrochlorothiazide monotherapy. 4.2 Posology and method of administration
Dosage CO-NORTIVAN'i The recommended urinary tract infection symptoms dose is one tablet once a day. The recommended dose titration of the individual components. In all cases, the individual components of the dose gradually increase the next dose, in order to reduce the risk of hypotension and other adverse events. If clinically indicated, may be considered a direct change from monotherapy to the fixed combination in patients with blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy, subject to compliance with the recommended urinary tract infection symptoms dose titration of the individual components of SEQ EKORDA. CO-NORTIVAN'i urinary tract infection symptoms achieved by the clinical response to treatment should be evaluated after initiating therapy and if blood pressure remains urinary tract infection symptoms uncontrolled, dose can be increased by increasing the dose of either component to a maximum dose of 320 mg / 25 mg. The antihypertensive effect is substantially within 2 weeks. In most patients, maximal effects of 4 weeks. However, some patients may need in order ... 4 to 8 weeks of treatment. This should be taken into account during dose titration. CO-NORTIVAN'i of administration may be taken with or without food and should be administered with water. Special Populations Renal impairment: Mild to moderate renal impairment (creatinine clearance> 30 mL / min) in patients with no dose adjustment is required. Due to the hydrochlorothiazide CO-NORTIVAN contraindicated in severe renal impairment (see sections 4.3, 4.4 and 5.2). Hepatic impairment: Mild to moderate hepatic impairment without cholestasis, the dose of valsartan patients should not exceed 80 mg (see section 4.4). Severe hepatic impairment, the CO-NORTIVAN contraindicated (see sections 4.3, 4.4 and 5.2). Elderly: Dose adjustment is not necessary in elderly patients. Pediatric patients with CO-NORTIVAN'i below 18 years of age is not recommended due to the lack of data on safety and efficacy. 4.3 Contraindications
- Hypersensitivity to valsartan, hydrochlorothiazide, other sulfonamide-peanut or any of the excipients. - Second and third trimesters of pregnancy (see sections 4.4 and 4.6). - Severe hepatic impairment, biliary cirrhosis urinary tract infection symptoms and cholestasis. - Severe renal impairment urinary tract infection symptoms (creatinine clearance urinary tract infection symptoms <30 ml / min), anuria. - Refractory hypokalemia, hyponatremia, hypercalcemia, hyperuricemia. 4.4 Special warnings and precautions for use
Serum electrolyte changes of derivatives, soybean oil, and the symptomatic Valsartan Concomitant use with potassium supplements, potassium-sparing